Tobramycin therapy of pulmonary infections in patients with cystic fibrosis.
D000617:Aminoglycosides / Q000032:analysis / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000032:analysis / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D003550:Cystic Fibrosis / Q000150:complications*; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D011549:Pseudomonas / Q000187:drug effects / Q000302:isolation & purification; D011552:Pseudomonas Infections / Q000188:drug therapy*; D013183:Sputum / Q000032:analysis / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013210:Staphylococcus / Q000187:drug effects / Q000302:isolation & purification
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents